共查询到20条相似文献,搜索用时 15 毫秒
1.
Hazzard WR 《The journals of gerontology. Series A, Biological sciences and medical sciences》2004,59(11):1161-2; discussion 1132-52
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
8-Oxo-deoxyguanosine: reduce, reuse, recycle? 总被引:1,自引:0,他引:1
Cooke MS Evans MD 《Proceedings of the National Academy of Sciences of the United States of America》2007,104(34):13535-13536
13.
Cardiovascular disease is the leading cause of mortality in patients with type 2 diabetes. Among the many factors that are
involved in the pathogenesis of atherosclerosis in diabetic patients, dyslipidemia plays a major role. It is characterized
by an increase in triglycerides, a decrease in high-density lipoprotein cholesterol and normal or mildly elevated low-density
lipoprotein cholesterol. The management of patients with diabetic dyslipidemia is difficult because we lack studies specifically
designed for diabetic patients. Thus, strategy has to rely on post hoc analyses of landmark intervention trials, which usually
include only a small number of diabetic patients, or on rare trials enrolling small cohorts of diabetic patients. When lifestyle
changes fail, monotherapy should be tried first with either a statin or a fibrate, depending on triglyceride level. If lipid
target values are not reached, a combination therapy can then be initiated, with close follow-up of potential side effects. 相似文献
14.
Chemotherapy depletes T cells in AIDS patients on HAART, but preexisting lymphopenia limits the scale compared with non-AIDS patients. Thus T-cell recovery time to baseline may be rapid, but the risk of additional AIDS-related complications persists. 相似文献
15.
16.
Viability imaging might be useful to guide decisions for revascularization in patients with ischemic cardiomyopathy. Recent trial results raise important points for clinicians regarding which modalities to use and in which patients. 相似文献
17.
18.
19.
20.
Dailey G 《Current diabetes reports》2005,5(5):329-332
Sulfonylurea compounds were the first available oral antidiabetic agents and they remain an important tool in our quest for
optimal glycemic control. The more recent introduction of meglitinides offers an approach to short-term insulin release with
minimal hypoglycemic risk during fasting periods. Published trials suggest that individuals with a hemoglobin A1c above 8.5% are unlikely to reach currently recommended targets (6.5% to 7%) without the use of one of these insulin secretagogues.
Starting and probable maximally effective doses for glimepiride are 1 to 2 mg initially and 4 mg thereafter. For glyburide
and glipizide, these are 2.5 to 5 mg initially, and 10 mg effective at a maximum. The large majority of the effect can be
seen within a week, making them very attractive when rapid lowering of glucose is needed. An understanding of the principles
will facilitate more effective use of initial and combination therapy. 相似文献